Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at cryptodailypress.com, will continue to monitor these healthtech companies to see if the momentum continues. CryptoDailyPress.com is also looking into these tickers COIN, CIFR, BTBT, RIOT, IBLC, HIVE, BITQ, BKCH, BBKCF..
Recent RAIN Stock Price: $1.26
Summary: Rain Oncology Inc. is a late-stage precision oncology company developing therapies which target oncogenic drivers to genetically select patients. The company's lead product candidate includes milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex which reactivates p53. Rain Oncology Inc., formerly known as Rain Therapeutics Inc., is based in NEWARK, Calif.
Mitchell Kapoor analyst at H.C. Wainwright reiterates coverage on Rain Therapeutics (RAIN) stock in the energy sector with a Hold rating and has not provided RAIN's stock price target.
In addition, TradingView issued a Sell rating for RAIN over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on RAIN. cryptodailypress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on RAIN, please click here >>
Ascendis Pharma, ASND
Recent ASND Stock Price: $91.30
Summary: Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark.
Andreas Argyrides analyst at Wedbush reiterates coverage on Ascendis Pharma (ASND) stock in the energy sector with a Buy rating and has set ASND's stock price target at $ 187.
In addition, TradingView issued a Buy rating for ASND over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on ASND. cryptodailypress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ASND, please click here >>
Cooper Co, COO
Recent COO Stock Price: $356.47
Summary: The Cooper Companies Inc, is a specialty medical device company operating on a global basis. Cooper has two business segments- CooperVision and CooperSurgical. CooperVision manufactures and sells a wide range of contact lenses. CooperVision develops manufactures and markets a broad range of single-use, two-week and monthly contact lenses, featuring advanced materials and optics. The company's products are primarily designed for solving vision challenges like astigmatism, presbyopia and ocular dryness.'CooperSurgical sells a variety of medical devices and surgical instruments that are primarily utilized by gynecologists and obstetricians.
Jeff Johnson analyst at Robert W. Baird reiterates coverage on Cooper Co (COO) stock in the energy sector with a Buy rating and has set COO's stock price target at $ 400.
In addition, TradingView issued a Sell rating for COO over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on COO. cryptodailypress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on COO, please click here >>
The editors at cryptodailypress.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
Click here to join thousands of investors who are interested in crypto currency, Bitcoin, blockchain technology and more.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.